Huanjingjian decoction

PreclinicalSmall molecule

SShanghai Pulmonary Hospital, Shanghai, China

Huanjingjian decoction is one of 14 small molecule programs targeting Premature ovarian insufficiency. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature Ovarian InsufficiencyActive, not recruiting

Premature Ovarian InsufficiencyPreclinical

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Premature Ovarian Insufficiency

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

—2

Zoladex

TTerSera Therapeutics LLC

Activella

1 4

Prometrium

Ferring

Phase 3

1 5

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 6

Rituxan

Roche

Phase 2

1 7

Depo-Provera

NEUPOGEN

1 9

Combined Oral Contraceptives

VViatris Innovation GmbH

Phase 3

1 10

Platelet Rich Plasma

ZZagazig University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

N/ANot yet recruiting

Premature Ovarian Insufficiency

NCT07020429

Clinical

Trials by Indication[1]

Premature ovarian insufficiency1 trial

Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·N/A·NCT07020429·276 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Huanjingjian decoction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Huanjingjian decoction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Huanjingjian decoction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

Huanjingjian decoction

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Premature ovarian insufficiency1 trial

References

Drug Info

Quick Facts

Related News